Condition: AML - Acute Myeloid Leukemia · Sponsor: Clinical Hub for Interventional Research (CHOIR)
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
This description comes directly from the study's public registry record.
John Pimanda, Professor · +61 000000000 · cosmos.jcsmr@anu.edu.au
Mark Polizzotto, Professor · cosmos.jcsmr@anu.edu.au
Always discuss trial participation with your own doctor first.
| Canberra Health Services | Canberra, Australian Capital Territory, Australia | Recruiting |
| Prince of Wales Hospital | Sydney, New South Wales, Australia | Recruiting |
| Royal North Shore Hospital | Sydney, New South Wales, Australia | Not Yet Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06782971